Clinical trial · Interventional
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Mastocytosis is a rare condition characterized by an accumulation of mast cell cells in one or more organs such as the liver, bone marrow, spleen and intestines. Its prevalence in the general population is 1 in 10,000. This pathology is due to the proliferation of a mast cell clone and the excessive release of inflammatory mediators which lead to abnormal tissue infiltration. To date, there are only a few cases reporting ocular and orbital manifestations of mastocytosis. Our prospective, interventional and single-center study consist in describing the ocular functional manifestations and ocular surface abnormalities of patients with systemic and cutaneous mastocytosis.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mast Cell Activation Disease | — | UNRESOLVED | — |
| Mast Cell Activation Syndrome | — | UNRESOLVED | — |
| Mast Cell Disease | Mastocytosis | ALIAS | 0.90 |
| Urticaria Pigmentosa | Urticaria Pigmentosa/Maculopapular Cutaneous Mastocytosis | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ophthalmological examination | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants affected by cutaneous and systemic mastocytosis
- description
- Participants affected by cutaneous and systemic mastocytosis with or without eye disabilities
- interventionNames
- Other: Ophthalmological examination
Primary outcomes (1)
- measure
- Proportion of Subjects with mastocytosis presenting eye abnormalities
- timeFrame
- up to 2 hours
- description
- Number of patients with functional complaints or abnormalities of the surface, orbit, anterior and posterior segment of the eyeball.
Secondary outcomes (2)
- measure
- Nature and Frequency of eye abnormalities
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have a diagnosis of mastocytosis * Male or female, 18 years of age and over * Ability to understand and provide written informed consent. Exclusion Criteria: * Disorders that do not allow good visualization of the posterior pole (cataract, intravitreal hemorrhage) * Patients with another ocular pathology that may bias the results (corneal dystrophy, dysthyroid orbitopathy, retinal pathologies) * History of refractive surgery
References
Publications (0)
Data not yet available